Samaneh Zandifar
1 
, Mahshid Imankhan
2 , Padideh Daneii
3 , Ali Azarpey
4* , Leila Alem
1* 1 Nickan Research Institute, Isfahan, Iran
2 Independent Researcher, 1514 Sheridan Rd NE apt 4014, Atlanta, Georgia, United States
3 Department of Cardiology, University of Florida Health, Jacksonville, Florida, United States
4 Emory University School of Medicine, Atlanta, Georgia, United States
Abstract
Immune checkpoint inhibitors work by blocking the “checkpoint” mechanism that tumors use to hide from the immune system, therefore also weakening the immune system. Consequently, checkpoint inhibitors can cause autoimmune reactions, resulting in adverse effects. Prompt identification and management of adverse effects are critical for patients under checkpoint inhibitor therapy due to the potential severity and unpredictability of these immune-related adverse events.
Implication for health policy/practice/research/medical education:
Checkpoint inhibitors can cause various adverse effects that need close monitoring and management, as prompt identification and proper management are critical. Patients under checkpoint inhibitor therapy should undergo regular monitoring and close communication with their clinical team to identify the signs and symptoms of any adverse reactions that may arise and manage them effectively.
Please cite this paper as: Zandifar S, Imankhan M, Daneii P, Azarpey A, ALem L. Nephrotoxicity of checkpoint inhibitors; a current challenge. J Nephropharmacol. 2024;13(1):e10641. DOI: 10.34172/npj.2023.10641.